01Evaxion Biotech A/S is scheduled to report Q2 2026 earnings on August 20, 2026 after market close, with analysts expecting earnings per share of -$0.01 compared to $0.00 in the prior year quarter.
02The company's stock trades at $3.14 with a market capitalization of $40.4 million, indicating a small-cap healthcare company.
03Recent earnings history shows the company has beaten estimates significantly, with Q1 2026 delivering a 95.7% positive surprise and Q4 2025 delivering an 89.5% positive surprise, though both quarters reported negative earnings per share.
Earnings Results
Evaxion Biotech A/S (NASDAQ:EVAX) is scheduled to report its Q2 earnings results on August 20, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.01, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $3.14 with a market capitalization of $40.4M.
Ahead of Evaxion Biotech A/S's earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Evaxion Biotech A/S should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.